Genomic Health, Inc.

Diana Cherbavaz

Tara Maddala

Michael R Crager

Mark Lee

Robert J Pelham

Steven Shak

Dejan Knezevic

William F Novotny

Carl L Millward

Audrey Goddard

Joffre B Baker

Michael C Kiefer

Wayne Cowens

Steve Shak

Frederick L Baehner

Robert Pelham

The present invention provides algorithm-based molecular assays that involve measurement of expression levels of genes, or their co-expressed genes, from a biological sample obtained from a prostate cancer patient. The genes may be grouped into functional gene subsets for calculating a quantitative score useful to predict a likelihood of a clinical outcome for a prostate cancer patient.

Gene expression profile algorithm and test for determining prognosis of prostate cancer

The present disclosure includes assays that involve measurement of expression levels of prognostic biomarkers, or co-expressed biomarkers, from a biological sample obtained from a prostate cancer patient, and analysis of the measured expression levels to provide information concerning the likely prognosis for the patient, and likelihood that the patient will have a recurrence of prostate cancer, or to classify the tumor by likelihood of clinical outcome or TMPRSS2 fusion status.

Method for using gene expression to determine prognosis of prostate cancer

Growing community of inventors

San Francisco, CA, United States of America

Diana Cherbavaz